华神科技：12月15日召开董事会会议

Group 1 - The core point of the article is that Huasheng Technology (SZ 000790) announced a board meeting to discuss the transfer of drug marketing licenses and related technologies, indicating strategic moves in their business operations [1] - For the first half of 2025, Huasheng Technology's revenue composition is as follows: 78.26% from the pharmaceutical sector, 17.99% from health services, 2.57% from other businesses, 1.06% from construction steel structures, and 0.12% from medical devices [1] - As of the report, Huasheng Technology has a market capitalization of 2.4 billion yuan [1]